Edition:
India

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

1.40USD
23 Feb 2018
Change (% chg)

$-0.03 (-2.10%)
Prev Close
$1.43
Open
$1.43
Day's High
$1.43
Day's Low
$1.38
Volume
5,515
Avg. Vol
18,134
52-wk High
$4.83
52-wk Low
$1.29

Select another date:

Tue, Jan 23 2018

BRIEF-Cardiome Announces Expanded Label For Aggrastat In China

* CARDIOME ANNOUNCES EXPANDED LABEL FOR AGGRASTAT® IN CHINA INCLUDING NEW STEMI INDICATION AND HIGH DOSE BOLUS REGIMEN

BRIEF-Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

* CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA

BRIEF-Cardiome Q3 loss per share $0.20

* Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

BRIEF-Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​

* Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​ Source text for Eikon: Further company coverage:

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

BRIEF-Basilea says distribution agreement with Cardiome

* BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH CARDIOME TO COMMERCIALIZE ANTIBIOTIC ZEVTERA/MABELIO (CEFTOBIPROLE) IN EUROPE AND ISRAEL

Select another date: